Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to be potent inhibitors of the cyclooxygenases. The present study was designed to investigate the effects of a cyclooxygenase (COX)-1 inhibitor, SC-560, administered alone or in combination with ibuprofen on the growth inhibition of s.c. human ovarian SKOV-3 carcinoma and on angiogenesis. The effects of SC-560 and ibuprofen on tumor growth inhibition have been examined in mouse ovarian cancer models. Angiogenesis of both COX inhibitors was measured by reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Prostaglandin E2 (PGE2) levels in tumor tissues of mice were also determined by ELISA. The inhibitory rates in SC-560 group alone and in combination with ibuprofen group were 21.21% and 41.55%, respectively. In combination therapy with SC-560 and ibuprofen, tumor volumes were significantly reduced compared with that of control group (P < 0.05). In treatment groups, both COX inhibitors significantly reduced intratumor PGE2 levels (all P < 0.01). Microvessel density (MVD) in tumor tissues were significantly decreased from 80.90 ± 5.14 in vehicle-treated to 40.70 ± 10.45 and 38.90 ± 8.41 in SC-560 group alone and combination ibuprofen therapy (all P < 0.01). Ibuprofen was similar to the cyclooxygenase-1-selective inhibitor SC-560 in its ability to suppress the values of MVD of tumor tissues. SC-560 administered alone or in combination with ibuprofen inhibited the COX-associated up-regulation of VEGF. These studies demonstrate synergism between two COX inhibitors and that antiangiogenic therapy can be used to inhibit ovarian cancer growth.
- Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002;29:32–42. doi:10.1053/sonc.2002.31594. CrossRef
- NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up. JAMA. 1995;273:491–7. doi:10.1001/jama.273.6.491. CrossRef
- Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003;4:431–6. doi:10.1016/S1535-6108(03)00310-6. CrossRef
- Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120. doi:10.1146/annurev.pharmtox.38.1.97. CrossRef
- Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69–1020. doi:10.1146/annurev.bi.55.070186.000441. CrossRef
- Seibert K, Masferrer J, Zhang Y, Leahy K, Hauser S, Gierse J. Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:125–7.
- Smith CJ, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA. 1998;95:13313–8. doi:10.1073/pnas.95.22.13313. CrossRef
- Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenterol Clin North Am. 1996;25:717–35. doi:10.1016/S0889-8553(05)70271-5. CrossRef
- Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104–7. doi:10.1016/S0140-6736(97)08064-1. CrossRef
- Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71–3.
- Gupta RA, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003;63:906–11.
- Daikoku T, et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006;66:2527–31. doi:10.1158/0008-5472.CAN-05-4063. CrossRef
- Daikoku T, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005;65:3735–44. doi:10.1158/0008-5472.CAN-04-3814. CrossRef
- Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology. 2001;142:3198–206. doi:10.1210/en.142.7.3198. CrossRef
- Williams CS, Watson AJM, Sheng H, Helou R, Sha J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000;60:6045–51.
- Ovidiu C, et al. Masferrer cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002;62:5778–84.
- Li W, Xu RJ, Jiang LH, Shi JF, Long X, Fan B. Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma. Med Oncol. 2005;22:63–70. doi:10.1385/MO:22:1:063. CrossRef
- Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875–87. doi:10.1093/jnci/84.24.1875. CrossRef
- Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer. 1997;73:33–7. doi :10.1002/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0.CO;2-2. CrossRef
- Min Y, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res. 2005;11:1618–28. doi:10.1158/1078-0432.CCR-04-1696. CrossRef
- Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16. doi:10.1016/S0092-8674(00)81433-6. CrossRef
- Kirsi N, Ari R, Martin M, Elizabeth S, Christian CH, Timothy HT. Transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J Biol Chem. 1997;272:21455–60. doi:10.1074/jbc.272.34.21455. CrossRef
- Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal. Int J Cancer. 2004;109:576–80. doi:10.1002/ijc.20012. CrossRef
- Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibitor of ovarian cancer growth. Cancer Res. 2000;60:2190–6.
- Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2002;62:165–70.
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
- Feldman Al, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer. 2000;89:1181–94. doi :10.1002/1097-0142(20000915)89:6<1181::AID-CNCR1>3.0.CO;2-T. CrossRef
- Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6. doi:10.1093/jnci/82.1.4. CrossRef
- Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res. 1994;54:276–80.
- Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst. 1998;90:447–54. doi:10.1093/jnci/90.6.447. CrossRef
- Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF. Vascular endothelial growth factor expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997;121:169–75. doi:10.1016/S0304-3835(97)00350-9. CrossRef
- Paley PJ, et al. Vascular endothelial growth factor expression in early stage 1 ovarian carcinomas. Cancer (Phila). 1997;80:98–106. doi :10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A. CrossRef
- Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vascular: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer. 1997;73:865–70. doi :10.1002/(SICI)1097-0215(19971210)73:6<865::AID-IJC17>3.0.CO;2-3. CrossRef
- Nagy JA, Ellen SM, Kemp TH, Eleanor JM, Ann MD, Harold FD. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res. 1995;55:376–85.
- Bryant CE, Appleton I, Mitchell JA. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells. Life Sci. 1998;62:2195–201. doi:10.1016/S0024-3205(98)00197-0. CrossRef
- Maldve RE, Kim Y, Muga SJ, Fischer SM. Prostaglandin E2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J Lipid Res. 2000;41:873–81.
- Dubois RN, Abramson SB, Crofford L. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–73.
- Yano T, Yano Y, Uchida M, Murakami A, Hagiwar K, Otani S, et al. The modulation effect of vitamin E on prostaglandin E2 level and ornithine decarboxylase activity at the promotion phase of lung tumorigenesis in mice. Biochem Pharmacol. 1997;53:1757–9. doi:10.1016/S0006-2952(96)00869-6. CrossRef
- Hanahan D, Folkma J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64. doi:10.1016/S0092-8674(00)80108-7. CrossRef
- Masferrer JL, Koki A, Seibert K. Cox-2 inhibitors, a new class of antiangiogenic agents. Ann NY Acad Sci. 1999;889:84–6. doi:10.1111/j.1749-6632.1999.tb08726.x. CrossRef
- Masferrer JL, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–11.
- Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995;36:127–37. doi:10.1007/BF00666035. CrossRef
- Yamamoto S, et al. Expression of vascular endothelial growth factor (VEGF) in epithelia ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer. 1997;76:1221–7.
- Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
- Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999;237:1–30.
- Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706–14. doi:10.1053/gast.2000.16510. CrossRef
- Kitamura T, et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002;23:1463–6. doi:10.1093/carcin/23.9.1463. CrossRef
- Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor
Volume 26, Issue 2 , pp 170-177
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Ovarian cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Gynecology and Obstetrics, Nanjing Medical University of Hangzhou Hospital, 310006, Hangzhou, China
- 2. Department of Pathology, Nanjing Medical University of Hangzhou Hospital, 310006, Hangzhou, China
- 3. Department of Laboratory, Nanjing Medical University of Hangzhou Hospital, 310006, Hangzhou, China